EGFR and non-small cell lung carcinoma: Monoclonal antibodies, such as cetuximab and panitumumab, and tyrosine kinase inhibitors (TKIs) have been developed and approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC), EGFR-expressing metastatic colorectal cancer (mCRC) with KRAS wild type, and head and neck cancers [100].